Chica­go-area au­toim­mune biotech gets phar­ma back­ing in $105M round for two PhII tri­als

COUR Phar­ma­ceu­ti­cals, a near­ly decade-old biotech work­ing on ther­a­pies for au­toim­mune dis­eases, said Tues­day it has raised $105 mil­lion in Se­ries A fund­ing to take it through Phase IIa stud­ies.

The Skok­ie, IL-based biotech had pre­vi­ous­ly reeled in about $100 mil­lion via ven­ture in­vestors and deals with Take­da and Iron­wood, CEO and founder John Pui­sis told End­points News. COUR, which is short for courage, is based on re­search out of Steve Miller’s lab at North­west­ern Uni­ver­si­ty, Pui­sis said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER